Eikon Therapeutics Is A Biotechnology Company Based In Californiafounded In 2014Thecompany Focuses On Innovativedrug Discovery By Integrating Advanced Engineeringhigh Performancecomputingand Biological Researchwith A Team Of 201Ae500 Professionalsincluding Research Scientists And Clinical Expertseikon Aims To Develop Therapies For Serious Illnessesparticularly In Oncology Eikon S Uniqueplatform Leverages Proprietary Technologies To Study Protein Behavior In Living Cellsit Employs Singlemoleculetracking And A Data Driven Approach That Combines Automation And Machinelearning To Enhancetarget Identification And Drug Screeningthecompany Has Several Clinical Stageprogramsincluding Eik1001A Tlr7 8 Co Agonist In Phaseiii Trials For Advanced Melanomaand Eik100 A Selectiveparp1 Inhibitor In Phasei Trials For Various Cancerseikon Has Raised Over $1 1 Billion To Support Its Clinical Programs And Pipelineexpansionemphasizing Collaboration And Transparency In Its Operations
